Cannabis Extract Effects on Metabolic Parameters and Gut Microbiota Composition in a Mice Model of NAFLD and Obesity

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2022 Jul 7

PMID 35795290

Authors

Gil Zandani

Sarit Anavi-Cohen

Tal Assa-Glazer

Jonathan Gorelick

Abraham Nyska

Noa Sela

Nirit Bernstein

Zecharia Madar

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver abnormalities and has been linked with metabolic syndrome hallmarks. Unfortunately, current treatments are limited. This work aimed to elucidate the effects of three cannabis extracts on metabolic alteration and gut microbiota composition in a mouse model of NAFLD and obesity. Male mice were fed with a high-fat diet (HFD) for 12 weeks. Following the establishment of obesity, the HFD-fed group was subdivided into HFD or HFD that was supplemented with one of three cannabis extracts (CN1, CN2, and CN6) for additional 8 weeks. Metabolic parameters together with intestinal microbiota composition were evaluated. Except for several minor changes in gene expression, no profound metabolic effect was found due to cannabis extracts addition. Nevertheless, marked changes were observed in gut microbiota diversity and composition, with CN1 and CN6 exhibiting microbial abundance patterns that are associated with more beneficial outcomes. Taken together, specific cannabis extracts' addition to an HFD results in more favorable modifications in gut microbiota. Although no marked metabolic effect was disclosed, longer treatments duration and/or higher extracts concentrations may be needed. More research is required to ascertain this conjecture and to establish the influence of various cannabis extracts on host health in general and NAFLD in particular.

Citing Articles

Effect of Dietary L. Residue Supplementation on Meat Quality and Flavor-Enhancing Free Amino Acids in Broiler Chickens.

Sopian Y, Sahatsanon K, Satsook A, Arjin C, Sringarm K, Lumsangkul C Animals (Basel). 2025; 15(5).

PMID: 40076041 PMC: 11898983. DOI: 10.3390/ani15050759.

Medicinal Cannabis and the Intestinal Microbiome.

Vitetta L, Nation T, Oldfield D, Thomsen M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770543 PMC: 11678570. DOI: 10.3390/ph17121702.

Hemp Extract () in the Treatment of Gastrointestinal Distress and Dyspepsia: Historical Insights from Barcelona, Spain.

Riboulet-Zemouli K, Allue Creus J Pharmaceuticals (Basel). 2025; 17(12).

PMID: 39770428 PMC: 11840289. DOI: 10.3390/ph17121585.

A Scoping Review on Hepatoprotective Mechanism of Herbal Preparations through Gut Microbiota Modulation.

Poo C, Lau M, Nasir N, Nik Zainuddin N, Rahman M, Mustapha Kamal S Curr Issues Mol Biol. 2024; 46(10):11460-11502.

PMID: 39451562 PMC: 11506797. DOI: 10.3390/cimb46100682.

Development of Delivery Systems with Prebiotic and Neuroprotective Potential of Industrial-Grade L.

Sip S, Stasilowicz-Krzemien A, Sip A, Szulc P, Neumann M, Kryszak A Molecules. 2024; 29(15).

PMID: 39124978 PMC: 11314201. DOI: 10.3390/molecules29153574.

References

Kim D, Kim W, Kwak M, Chung G, Yim J, Ahmed A . Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States. PLoS One. 2017; 12(10):e0186702. PMC: 5648282. DOI: 10.1371/journal.pone.0186702. View

Zhang C, Zhang Y, Li H, Liu X . The potential of proteins, hydrolysates and peptides as growth factors for Lactobacillus and Bifidobacterium: current research and future perspectives. Food Funct. 2020; 11(3):1946-1957. DOI: 10.1039/c9fo02961c. View

Palmas V, Pisanu S, Madau V, Casula E, Deledda A, Cusano R . Gut microbiota markers associated with obesity and overweight in Italian adults. Sci Rep. 2021; 11(1):5532. PMC: 7943584. DOI: 10.1038/s41598-021-84928-w. View

Costea P, Hildebrand F, Arumugam M, Backhed F, Blaser M, Bushman F . Enterotypes in the landscape of gut microbial community composition. Nat Microbiol. 2017; 3(1):8-16. PMC: 5832044. DOI: 10.1038/s41564-017-0072-8. View

Zuardi A . Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Braz J Psychiatry. 2008; 30(3):271-80. DOI: 10.1590/s1516-44462008000300015. View

Smith N, Soriano-Arroquia A, Goljanek-Whysall K, Jackson M, McDonagh B . Redox responses are preserved across muscle fibres with differential susceptibility to aging. J Proteomics. 2018; 177:112-123. PMC: 5884322. DOI: 10.1016/j.jprot.2018.02.015. View

Magne F, Gotteland M, Gauthier L, Zazueta A, Pesoa S, Navarrete P . The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients?. Nutrients. 2020; 12(5). PMC: 7285218. DOI: 10.3390/nu12051474. View

Gurung M, Li Z, You H, Rodrigues R, Jump D, Morgun A . Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020; 51:102590. PMC: 6948163. DOI: 10.1016/j.ebiom.2019.11.051. View

Wieland A, Frank D, Harnke B, Bambha K . Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015; 42(9):1051-63. DOI: 10.1111/apt.13376. View

10.

Ley R, Backhed F, Turnbaugh P, Lozupone C, Knight R, Gordon J . Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005; 102(31):11070-5. PMC: 1176910. DOI: 10.1073/pnas.0504978102. View

11.

Verdelho Machado M, Cortez-Pinto H . Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016; 17(4):481. PMC: 4848937. DOI: 10.3390/ijms17040481. View

12.

Mathur R, Barlow G . Obesity and the microbiome. Expert Rev Gastroenterol Hepatol. 2015; 9(8):1087-99. DOI: 10.1586/17474124.2015.1051029. View

13.

Cotter T, Rinella M . Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020; 158(7):1851-1864. DOI: 10.1053/j.gastro.2020.01.052. View

14.

Ciobarca D, Catoi A, Copaescu C, Miere D, Crisan G . Bariatric Surgery in Obesity: Effects on Gut Microbiota and Micronutrient Status. Nutrients. 2020; 12(1). PMC: 7019602. DOI: 10.3390/nu12010235. View

15.

Scherer T, Buettner C . The dysregulation of the endocannabinoid system in diabesity-a tricky problem. J Mol Med (Berl). 2009; 87(7):663-8. PMC: 3253348. DOI: 10.1007/s00109-009-0459-y. View

16.

Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

17.

Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L . A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2016; 23(1):107-113. DOI: 10.1038/nm.4236. View

18.

Silvestri C, Paris D, Martella A, Melck D, Guadagnino I, Cawthorne M . Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. J Hepatol. 2015; 62(6):1382-90. DOI: 10.1016/j.jhep.2015.01.001. View

19.

Greer R, Dong X, Moraes A, Zielke R, Fernandes G, Peremyslova E . Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism. Nat Commun. 2016; 7:13329. PMC: 5114536. DOI: 10.1038/ncomms13329. View

20.

De Filippis F, Pasolli E, Ercolini D . The food-gut axis: lactic acid bacteria and their link to food, the gut microbiome and human health. FEMS Microbiol Rev. 2020; 44(4):454-489. PMC: 7391071. DOI: 10.1093/femsre/fuaa015. View